A research report proposed that SLCO2A1, a prostaglandin transporter, plays a significant role in maintaining the concentration and release of PGE2 and also stated that SLCO2A1 pharmacological intervention may possess robust scope for developing CRC therapeutics [129]. Here, SLCO2A1 is linked to colorectal carcinoma.